Form 4 for RYTM RHYTHM PHARMACEUTICALS, INC.
Accepted 2024-02-05 00:00:00 ET · period of report 2024-02-01 · accession 0001104659-24-010800 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-05 | 2024-02-01 | RYTM | Lee Jennifer Kayden | EVP, Head of North America | S - Sale+OE | $45.06 | -1,492 | 3,021 | -33% | -$67.2K |
| D | 2024-02-05 | 2024-02-01 | RYTM | Lee Jennifer Kayden | EVP, Head of North America | M - OptEx | — | +4,513 | 4,513 | New | — |
| D | 2024-02-05 | 2024-02-01 | RYTM | Lee Jennifer Kayden | EVP, Head of North America | M - OptEx | $0.00 | -4,513 | 13.5K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-01 | S | D | 1,492 | $45.06 | 3,021 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-01 | M | A | 4,513 | — | 4,513 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. |
| 3 | Derivative | Restricted Stock Units | 2024-02-01 | M | D | 4,513 | $0.00 | 13,537 | D | — · — to — | 4,513 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. (F3) The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. |